Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees

Hepatology

Volumn 32, Issue 3, 2000, Pages 588-596

  Eren, Rachel ^a   Ilan, Ehud ^a   Nussbaum, Ofer ^a   Lubin, Ido ^a   Terkieltaub, Dov ^a   Arazi, Yossi ^a   Ben Moshe, Ofer ^a   Kitchinzky, Alberto ^a   Berr, Shoshana ^a   Gopher, Judy ^a   Zauberman, Arie ^a   Galun, Eithan ^b   Shouval, Danny ^b   Daudi, Nili ^b   Eid, Ahamed ^b   Jurim, Oded ^b   Magnius, Lars O ^c   Hammas, Berit ^c   Reisner, Yair ^d   Dagan, Shlomo ^a  

^a XTL Biopharmaceuticals Ltd Israel   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 17.1.41; MONOCLONAL ANTIBODY 19.79.5; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CHIMERA; CHIMPANZEE; CONTROLLED STUDY; DISEASE CARRIER; DOSE RESPONSE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS LOAD; VIRUS NEUTRALIZATION;

EID: 0033840084     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.9632     Document Type: Article

References (42)

1. Natural course of HBV infection
2. Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers
3. Liver transplantation in European patients with the hepatitis B surface antigen
4. Hepatitis B virus vaccines
5. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization
6. Successful retransplantation for recurrent posttransplant hepatitis B virus infection in the primary allograft
7. Liver transplantation in hepatitis B surface antigen positive patients with postoperative long-term immunoprophylaxis
8. Intravenous or intramuscular anti-HBs immunoglobulin for the prevention of hepatitis B reinfection after orthotopic liver transplantation
9. Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation
10. Establishment of hybridomas secreting human monoclonal antibodies against tetanus toxin and hepatitis B virus surface antigen
11. Human-human hybridomas secreting hepatitis B virus-neutralizing antibodies
12. Effective production of anti-tetanus toxoid and anti-HBsAg human monoclonal antibodies by serum-free culture of hybridomas
13. Characterization of human monoclonal antibodies directed against hepatitis B surface antigen
14. Efficient production of anti- (hepatitis B virus) antibodies and their neutralizing activity in chimpanzees
15. Anti-hepatitis B virus activity of a mixture of two monoclonal antibodies in an 'inhibition in solution' assay
16. Markedly prolonged incubation period of hepatitis B in a chimpanzee passively immunized with a human monoclonal antibody to the a determinant of hepatitis B surface antigen
17. In vivo activity of a mixture of two human monoclonal antibodies (anti-HBs) in a chronic hepatitis B virus carrier chimpanzee
18. Human monoclonal antibodies specific to hepatitis B virus generated in a human/mouse radiation chimera: The trimera system
19. Cell-based and animal models for hepatitis B and C viruses
20. Hepatitis C and hepatitis B animal models
21. The hepatitis B virus-trimera mouse: A model for human HBV infection and evaluation of anti-HBV therapeutic agents
22. Diasterocontrol in glycosylation reactions: Synthesis off β-D and β-L dideoxycytidine analogues
23. 2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo
24. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene
25. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin
26. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization
27. Prevention of hepatitis B 'rerecurrence' after a second liver transplant - The role of maintenance polyclonal HBIG therapy
28. Retransplantation of patients with severe posttransplant hepatitis B in the first allograft
29. Gly145 to Arg substitution in HBs antigen of immune escape mutant of hepatitis B virus
30. Mutations in the envelope gene of hepatitis B virus variants co-occurring with antibody to surface antigen in sera from patients with chronic hepatitis B
31. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis
32. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin
33. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients
34. Analysis of the antigenic epitopes of hepatitis B surface antigen involved in the induction of a protective antibody response
35. Monoclonal antibodies and hepatitis B: A new perspective using highly sensitive and specific radio-immunoassays
36. Hepatitis B surface antigen variation and protective immunity
37. HBV and HDV replication in experimental models: Effect of interferon
38. Experience with lamivudine against hepatitis B virus
39. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group
40. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
41. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
42. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors